Ronald Simon

List of Publications by Year
in descending order

413 papers	21,889 citations	13827 67 h-index	14702 127 g-index
422 all docs	422 docs citations	422 times ranked	27021 citing authors

#	Article	IF	Citations
1	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 433-447.	1.4	11
2	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Therapy, 2022, 29, 49-61.	2.2	3
3	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. American Journal of Surgical Pathology, 2022, 46, 97-104.	2.1	18
4	Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence. Laboratory Investigation, 2022, 102, 650-657.	1.7	5
5	Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers. , 2022, , .		0
6	Abstract P069: Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2022, , .		0
7	PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power. Cancers, 2022, 14, 1267.	1.7	7
8	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Experimental and Molecular Pathology, 2022, 126, 104762.	0.9	15
9	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology, 2022, 89, 245-258.	1.9	15
10	Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. Human Pathology, 2022, 126, 108-120.	1.1	4
11	Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	1
12	Immune phenotypes and T-cell density at the invasive margin correlate with prognosis in epithelial vulvar cancer.. Journal of Clinical Oncology, 2022, 40, 5599-5599.	0.8	0
13	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211065.	1.0	1
14	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	1.2	11
15	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World Journal of Urology, 2021, 39, 829-837.	1.2	3
16	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. International Journal of Cancer, 2021, 148, 748-758.	2.3	3
17	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10â€¦399 Tissue Samples. Technology in Cancer Research and Treatment, 2021, 20, 153303382110433.	0.8	10
18	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. Cancer Biology and Medicine, 2021, 18, 245-255.	1.4	13

#	Article	IF	Citations
19	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, e29-e38.	0.6	6
20	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	2.8	33
21	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. Molecular Oncology, 2021, 15, 1956-1969.	2.1	5
22	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Molecular Medicine, 2021, 27, 16.	1.9	32
23	Y-chromosome loss is frequent in male renal tumors. Annals of Translational Medicine, 2021, 9, 209-209.	0.7	13
24	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	0.6	3
25	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	0.9	12
26	Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers. Cellular Oncology (Dordrecht), 2021, 44, 793-803.	2.1	29
27	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	0.6	11
28	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 2021, 9, 397.	1.4	42
29	Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer. Aging, 2021, 13, 14590-14603.	1.4	5
30	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomarker Research, 2021, 9, 44.	2.8	30
31	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2879-2884.	1.2	1
32	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Acta OncolÃ³gica, 2021, 60, 1210-1217.	0.8	10
33	Abstract 2735: Clinical significance of CD4+CD7â˜˜helper T-cells and tumoral CD7 expression in colorectal cancer. , 2021, , .		0
34	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0
35	Abstract 2773: Deep profiling of the PD-1/PD-L1 pathway in 10000 cancers revealed changes in the immune cell composition between cancer entities. , 2021, , .		0
36	Abstract 2775: PD-L1 expression in human tumors: a tissue microarray study on 5,561 tissue samples and 87 tumor types. , 2021, , .		0

#	Article	IF	Citations
37	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		0
38	MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. Pathology Research and Practice, 2021, 224, 153533.	1.0	3
39	Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. Cancer Investigation, 2021, 39, 711-720.	0.6	6
40	High mitochondrial content is associated with breast cancer aggressiveness. Molecular and Clinical Oncology, 2021, 15, 203.	0.4	3
41	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. PeerJ, 2021, 9, e11905.	0.9	4
42	Pattern of placental alkaline phosphatase (<scp>PLAP</scp>) expression in human tumors: a tissue microarray study on 12,381 tumors. Journal of Pathology: Clinical Research, 2021, 7, 577-589.	1.3	12
43	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. Human Pathology, 2021, 115, 19-36.	1.1	19
44	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. Annals of Diagnostic Pathology, 2021, 54, 151793.	0.6	11
45	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a <i>ROS1</i> p.L1950F Mutation: Case Report. Oncology Research and Treatment, 2021, 44, 495-502.	0.8	5
46	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. Medical Molecular Morphology, 2021, 54, 156-165.	0.4	9
47	P02.06â€‰Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2021, , .		0
48	P02.03â€‰Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers. , 2021, , .		0
49	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. Pathology Research and Practice, 2021, 228, 153663.	1.0	11
50	6q deletion is frequent but unrelated to patient prognosis in breast cancer. Breast Cancer, 2021, , 1.	1.3	1
51	Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. American Journal of Clinical Pathology, 2021, 156, S137-S138.	0.4	0
52	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. Diagnostics, 2021, 11, 2351.	1.3	2
53	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours. Biomedicines, 2021, 9, 1831.	1.4	7
54	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. Cancer Medicine, 2020, 9, 1409-1418.	1.3	5

#	ARTICLE	IF	CITATIONS
55	High RSF1 protein expression is an independent prognostic feature in prostate cancer. Acta Oncológica, 2020, 59, 268-273.	0.8	4
56	Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer. Molecular Oncology, 2020, 14, 129-138.	2.1	19
57	High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 745-752.	1.4	17
58	High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. International Journal of Colorectal Disease, 2020, 35, 259-268.	1.0	17
59	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 43.e13-43.e20.	0.8	8
60	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World Journal of Urology, 2020, 38, 2185-2196.	1.2	10
61	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by *PTEN* -loss. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3637-3647.	3.3	17
62	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. Pathology and Oncology Research, 2020, 26, 2709-2722.	0.9	7
63	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. Biomedicines, 2020, 8, 215.	1.4	2
64	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. BioMed Research International, 2020, 2020, 1-13.	0.9	7
65	High B7‐H3 expression is linked to increased risk of prostate cancer progression. Pathology International, 2020, 70, 733-742.	0.6	16
66	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. European Journal of Cancer, 2020, 137, 93-107.	1.3	10
67	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical and Experimental Metastasis, 2020, 37, 649-656.	1.7	4
68	P03.01…Prevalence of CD112R+immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment. , 2020, 8, A22.1-A22.		0
69	P03.10…Prevalence and prognostic role of FoxP3[+]regulatory T lymphocytes in cancer. A tissue microarray study on >20'000 cancers. , 2020, , .		0
70	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. Cells, 2020, 9, 2337.	1.8	13
71	P03.06…Pattern of Ki67[+]expanding CD8[+]cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment. , 2020, , .		0
72	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. BMC Cancer, 2020, 20, 1220.	1.1	12

#	Article	IF	Citations
73	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. Disease Markers, 2020, 2020, 1-10.	0.6	4
74	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 625-636.	1.4	6
75	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. World Journal of Surgical Oncology, 2020, 18, 128.	0.8	3
76	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers. Scientific Reports, 2020, 10, 8916.	1.6	14
77	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Molecular Medicine, 2020, 26, 24.	1.9	5
78	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusionâ€positive prostate cancers. International Journal of Cancer, 2020, 147, 575-583.	2.3	4
79	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cellular Oncology (Dordrecht), 2020, 43, 421-430.	2.1	23
80	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocrine Pathology, 2020, 31, 182-189.	5.2	15
81	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. Annals of Surgical Oncology, 2020, 27, 3997-4006.	0.7	20
82	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. Gastroenterology, 2020, 159, 1417-1430.e3.	0.6	31
83	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERGâ€negative prostate cancer. Prostate, 2020, 80, 1097-1107.	1.2	10
84	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 488-495.	0.8	19
85	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications, 2020, 11, 139.	5.8	44
86	High homogeneity of MMR deficiency in ovarian cancer. Gynecologic Oncology, 2020, 156, 669-675.	0.6	24
87	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. Pathology, 2020, 52, 421-430.	0.3	5
88	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e1-605.e8.	0.8	3
89	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. Pathology International, 2020, 70, 441-451.	0.6	8
90	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget, 2020, 11, 237-249.	0.8	19

#	ARTICLE	IF	CITATIONS
91	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget, 2020, 11, 1007-1016.	0.8	14
92	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. Neoplasia, 2019, 21, 872-881.	2.3	5
93	Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology Letters, 2019, 18, 1497-1502.	0.8	7
94	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. Tumor Biology, 2019, 41, 101042831882481.	0.8	9
95	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. BMC Cancer, 2019, 19, 944.	1.1	4
96	A shift from membranous and stromal syndecanâ€1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Molecular Carcinogenesis, 2019, 58, 2306-2315.	1.3	14
97	Random forest-based modelling to detect biomarkers for prostate cancer progression. Clinical Epigenetics, 2019, 11, 148.	1.8	89
98	Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. Disease Markers, 2019, 2019, 1-13.	0.6	47
99	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers, 2019, 11, 835.	1.7	109
100	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of <i>PTEN</i> deleted prostate cancers. Cancer Biology and Medicine, 2019, 16, 319.	1.4	2
101	Hyperparameter optimization for image analysis: application to prostate tissue images and live cell data of virus-infected cells. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 1847-1857.	1.7	6
102	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Disease Markers, 2019, 2019, 1-6.	0.6	12
103	SNW1 is a prognostic biomarker in prostate cancer. Diagnostic Pathology, 2019, 14, 33.	0.9	7
104	16p13.11 microdeletion uncovers lossâ€ofâ€function of a <i>MYH11</i> missense variant in a patient with megacystisâ€microcolonâ€intestinalâ€hypoperistalsis syndrome. Clinical Genetics, 2019, 96, 85-90.	1.0	20
105	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncology Letters, 2019, 17, 3826-3834.	0.8	19
106	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. BMC Cancer, 2019, 19, 193.	1.1	24
107	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. Disease Markers, 2019, 2019, 1-11.	0.6	38
108	Loss of CCAATâ€enhancerâ€binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Prostate, 2019, 79, 302-311.	1.2	4

#	Article	IF	Citations
109	5q21 deletion is often heterogeneous in prostate cancer. Genes Chromosomes and Cancer, 2019, 58, 509-515.	1.5	4
110	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging, 2019, 11, 7796-7804.	1.4	33
111	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. Aging, 2019, 11, 7859-7879.	1.4	28
112	A nuclear shift of GSK3Î² protein is an independent prognostic factor in prostate cancer. Oncotarget, 2019, 10, 1729-1744.	0.8	2
113	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. Oncotarget, 2019, 10, 4973-4986.	0.8	5
114	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget, 2019, 10, 5439-5453.	0.8	22
115	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. Oncotarget, 2019, 10, 7096-7111.	0.8	4
116	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncology Letters, 2019, 18, 5107-5118.	0.8	9
117	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncology Reports, 2018, 39, 3-12.	1.2	50
118	Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. Scientific Reports, 2018, 8, 3947.	1.6	54
119	<scp>EZH</scp>2 overexpression in head and neck cancer is related to lymph node metastasis. Journal of Oral Pathology and Medicine, 2018, 47, 240-245.	1.4	16
120	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC Cancer, 2018, 18, 37.	1.1	16
121	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. World Journal of Urology, 2018, 36, 877-882.	1.2	26
122	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Letters, 2018, 423, 60-70.	3.2	31
123	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	0.9	40
124	Upregulation of centromere protein F is linked to aggressive prostate cancers. Cancer Management and Research, 2018, Volume 10, 5491-5504.	0.9	17
125	High expression of class III Î²â€‘tubulin in upper gastrointestinal cancer types. Oncology Letters, 2018, 16, 7139-7145.	0.8	10
126	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. Scientific Reports, 2018, 8, 17535.	1.6	23

#	ARTICLE	IF	CITATIONS
127	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. BMC Cancer, 2018, 18, 1209.	1.1	28
128	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. BMC Cancer, 2018, 18, 1106.	1.1	9
129	Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. Cancer Management and Research, 2018, Volume 10, 5909-5917.	0.9	3
130	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018, 34, 996-1011.e8.	7.7	190
131	High concordance of TMPRSS–ERG fusion between primary prostate cancer and its lymph node metastases. Oncology Letters, 2018, 16, 6238-6244.	0.8	3
132	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e19-531.e25.	0.8	17
133	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e243-e246.	0.5	18
134	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. Experimental and Molecular Pathology, 2018, 105, 50-56.	0.9	6
135	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes and Cancer, 2018, 57, 504-512.	1.5	35
136	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC Cancer, 2018, 18, 612.	1.1	19
137	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	0.9	58
138	Abstract 696: Patterns of TIGIT expression in normal lymphatic tissue, inflammation and cancer. , 2018, , .		2
139	Internationales Krebsgenomkonsortium (ICGC). Medizinische Genetik, 2017, 28, 416-423.	0.1	0
140	β III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Human Pathology, 2017, 61, 210-220.	1.1	23
141	MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays. Journal of Mass Spectrometry, 2017, 52, 165-173.	0.7	29
142	Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without <i>TMPRSS2:ERG</i> fusion. Molecular Carcinogenesis, 2017, 56, 2135-2145.	1.3	19
143	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia, 2017, 19, 279-287.	2.3	16
144	High concordance of findings obtained from transgluteal magnetic resonance imaging –and transrectal ultrasonography–guided biopsy as compared with prostatectomy specimens. BJU International, 2017, 120, 365-376.	1.3	3

#	Article	IF	Citations
145	The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer. Oncogene, 2017, 36, 4124-4134.	2.6	60
146	THSD7A expression in human cancer. Genes Chromosomes and Cancer, 2017, 56, 314-327.	1.5	45
147	High‐Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. Prostate, 2017, 77, 1528-1538.	1.2	16
148	Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers. Tumor Biology, 2017, 39, 101042831771216.	0.8	51
149	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. Carcinogenesis, 2017, 38, 1180-1187.	1.3	15
150	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. Neoplasia, 2017, 19, 707-715.	2.3	65
151	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	5.8	100
152	High‐level β‑III‑tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. Journal of Oral Pathology and Medicine, 2017, 46, 986-990.	1.4	14
153	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. Scientific Reports, 2017, 7, 2056.	1.6	27
154	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. Carcinogenesis, 2017, 38, 19-27.	1.3	51
155	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods, 2017, 114, 60-73.	1.9	15
156	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. Clinical Oral Investigations, 2017, 21, 1503-1508.	1.4	2
157	High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 286.	1.8	30
158	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC Cancer, 2017, 17, 504.	1.1	9
159	Deletion of 8p is an independent prognostic parameter in prostate cancer. Oncotarget, 2017, 8, 379-392.	0.8	36
160	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. Oncotarget, 2017, 8, 31494-31508.	0.8	10
161	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget, 2017, 8, 65566-65576.	0.8	56
162	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. Oncotarget, 2017, 8, 108923-108935.	0.8	26

#	Article	IF	Citations
163	Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer, 2016, 23, 111-119.	1.3	33
164	Loss of <scp>RNA</scp>â€binding motif protein 3 expression is associated with rightâ€sided localization and poor prognosis in colorectal cancer. Histopathology, 2016, 68, 191-198.	1.6	21
165	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate, 2016, 76, 259-272.	1.2	27
166	Diverse expression patterns of the <scp>EMT</scp> suppressor grainyheadâ€like 2 (<scp>GRHL</scp>2) in normal and tumour tissues. International Journal of Cancer, 2016, 138, 949-963.	2.3	18
167	High levels of class III Î²-tubulin expression are associated with aggressive tumor features in breast cancer. Oncology Letters, 2016, 11, 1987-1994.	0.8	39
168	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2802-2811.	3.2	21
169	Loss of <i>CHD1</i> causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Reports, 2016, 17, 1609-1623.	2.0	88
170	Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. Molecular Medicine Reports, 2016, 14, 1443-1450.	1.1	8
171	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumor Biology, 2016, 37, 12655-12663.	0.8	20
172	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. BMC Cancer, 2016, 16, 641.	1.1	24
173	Reduced <scp>AZGP1</scp> expression is an independent predictor of early <scp>PSA</scp> recurrence and associated with ERGâ€fusion positive and <scp><i>PTEN</i></scp> deleted prostate cancers. International Journal of Cancer, 2016, 138, 1199-1206.	2.3	30
174	Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections. Journal of Analytical Atomic Spectrometry, 2016, 31, 801-808.	1.6	26
175	Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma. Child's Nervous System, 2016, 32, 281-290.	0.6	7
176	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. Pathology and Oncology Research, 2016, 22, 95-102.	0.9	19
177	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2016, 69, 592-598.	0.9	212
178	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. Human Pathology, 2016, 48, 102-110.	1.1	18
179	High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology, 2016, 69, 209-214.	1.0	114
180	Tissue Microarrays. Methods in Molecular Biology, 2016, 1381, 53-65.	0.4	37

#	Article	IF	Citations
181	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget, 2016, 7, 81322-81331.	0.8	31
182	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget, 2016, 7, 86339-86349.	0.8	24
183	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget, 2016, 7, 3897-3904.	0.8	8
184	PSMA Expression is Highly Homogenous in Primary Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 449-455.	0.6	33
185	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. International Journal of Cancer, 2015, 137, 2354-2363.	2.3	39
186	Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer, 2015, 15, 963.	1.1	30
187	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagnostic Pathology, 2015, 10, 125.	0.9	25
188	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. PLoS ONE, 2015, 10, e0128525.	1.1	26
189	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. PLoS ONE, 2015, 10, e0134614.	1.1	16
190	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget, 2015, 6, 12822-12834.	0.8	34
191	Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. Pathology and Oncology Research, 2015, 21, 1183-1189.	0.9	8
192	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. International Journal of Oncology, 2015, 46, 1637-1642.	1.4	13
193	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. Oncology Reports, 2015, 34, 1211-1220.	1.2	12
194	Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer. Cancer Research, 2015, 75, 720-731.	0.4	36
195	βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 1561-1569.	1.2	14
196	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterology, 2015, 15, 7.	0.8	101
197	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. International Journal of Molecular Sciences, 2015, 16, 8591-8606.	1.8	4
198	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. Experimental and Molecular Pathology, 2015, 98, 419-426.	0.9	26

#	ARTICLE	IF	CITATIONS
199	Saccharomyces cerevisiaeâ€"like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusionâ€"positive and fusion-negative cancers. Human Pathology, 2015, 46, 514-523.	1.1	10
200	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis, 2015, 36, 1333-1340.	1.3	48
201	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	13.5	2,435
202	Î²III-tubulin overexpression is linked to left-sided tumor localization and nuclear Î²-catenin expression in colorectal cancer. Cancer Treatment Communications, 2015, 4, 96-102.	0.4	0
203	8p deletion is strongly linked to poor prognosis in breast cancer. Cancer Biology and Therapy, 2015, 16, 1080-1087.	1.5	26
204	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer, 2015, 15, 538.	1.1	30
205	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. Clinical Cancer Research, 2015, 21, 3471-3479.	3.2	43
206	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature Genetics, 2015, 47, 22-30.	9.4	141
207	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLoS ONE, 2015, 10, e0141867.	1.1	16
208	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget, 2015, 6, 8377-8387.	0.8	44
209	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget, 2015, 6, 27966-27979.	0.8	30
210	The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5027-5027.	0.8	0
211	Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. International Journal of Clinical and Experimental Pathology, 2015, 8, 7009-15.	0.5	7
212	High intratumoral FOXP3â‚ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 8227-35.	0.5	24
213	The Multifunctional Growth Factor Midkine Promotes Proliferation and Migration in Pancreatic Cancer. Molecular Cancer Research, 2014, 12, 670-680.	1.5	39
214	Patterns of ALK expression in different human cancer types. Journal of Clinical Pathology, 2014, 67, 477-481.	1.0	5
215	High nuclear karyopherin Î± 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Modern Pathology, 2014, 27, 96-106.	2.9	25
216	The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. International Journal of Cancer, 2014, 135, 1399-1407.	2.3	30

#	Article	IF	Citations
217	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	2.9	69
218	MALDI imagingâ€"based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays1These authors contributed equally to this work.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1225-1233.	0.8	27
219	Clinical significance of different types of <i>p53</i> gene alteration in surgically treated prostate cancer. International Journal of Cancer, 2014, 135, 1369-1380.	2.3	95
220	FISH Oracle 2: a web server for integrative visualization of genomic data in cancer research. Journal of Clinical Bioinformatics, 2014, 4, 5.	1.2	5
221	Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer. Clinical Cancer Research, 2014, 20, 1791-1802.	3.2	28
222	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. Microarrays (Basel, Switzerland), 2014, 3, 137-158.	1.4	2
223	CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clinical Oral Investigations, 2014, 18, 269-276.	1.4	42
224	Î²III-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	1.9	48
225	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. Prostate, 2014, 74, 1012-1022.	1.2	10
226	Immunohistochemical and <scp>FISH</scp> analysis of <scp>EGFR</scp> and its prognostic value in patients with oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2014, 43, 205-210.	1.4	32
227	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. European Journal of Cancer, 2014, 50, 852-861.	1.3	34
228	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	0.9	54
229	Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer. Cell Reports, 2014, 8, 798-806.	2.9	219
230	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelialâ€"mesenchymal transition and PI3K alterations. Gynecologic Oncology, 2014, 134, 599-606.	0.6	8
231	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.2	5
232	P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region. Clinical Oral Investigations, 2014, 18, 211-217.	1.4	6
233	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. International Journal of Oncology, 2014, 44, 609-615.	1.4	48
234	Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncology Reports, 2014, 32, 2628-2634.	1.2	22

#	Article	IF	Citations
235	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Research, 2014, 34, 2255-61.	0.5	28
236	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive *ERG* fusion-positive prostate cancers. Journal of Pathology, 2013, 231, 130-141.	2.1	118
237	Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis. British Journal of Cancer, 2013, 109, 1848-1858.	2.9	56
238	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate, 2013, 73, 1690-1698.	1.2	38
239	Overexpression of the chromatin remodeler death-domain–associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Human Pathology, 2013, 44, 1789-1796.	1.1	21
240	High mitochondria content is associated with prostate cancer disease progression. Molecular Cancer, 2013, 12, 145.	7.9	50
241	Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. Breast Cancer Research and Treatment, 2013, 137, 745-753.	1.1	41
242	Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. Human Pathology, 2013, 44, 1524-1533.	1.1	20
243	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Molecular Oncology, 2013, 7, 1001-1011.	2.1	47
244	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. European Journal of Cancer, 2013, 49, 1273-1279.	1.3	101
245	Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Experimental and Molecular Pathology, 2013, 95, 227-234.	0.9	13
246	Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC). Journal of Cranio-Maxillo-Facial Surgery, 2013, 41, 845-849.	0.7	16
247	Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer. Cancer Cell, 2013, 23, 159-170.	7.7	292
248	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, 2118-2126.	2.3	95
249	MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. Histopathology, 2013, 63, 455-462.	1.6	21
250	*PTEN* deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology, 2013, 63, 670-677.	1.6	30
251	Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer, 2013, 79, 221-227.	0.9	21
252	Loss of p^{Ser2448}-mTOR expression is linked to adverse prognosis and tumor progression in *ERG*-fusion-positive cancers. International Journal of Cancer, 2013, 132, 1333-1340.	2.3	37

#	Article	IF	Citations
253	Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Modern Pathology, 2013, 26, 733-742.	2.9	36
254	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Modern Pathology, 2013, 26, 975-983.	2.9	127
255	Marked heterogeneity of ERG expression in large primary prostate cancers. Modern Pathology, 2013, 26, 106-116.	2.9	62
256	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncology Letters, 2013, 6, 1245-1252.	0.8	21
257	High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. Clinical Cancer Research, 2013, 19, 2331-2341.	3.2	35
258	<i>CHD1</i> Is a 5q21 Tumor Suppressor Required for <i>ERG</i> Rearrangement in Prostate Cancer. Cancer Research, 2013, 73, 2795-2805.	0.4	188
259	Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. Journal of Clinical Pathology, 2013, 66, 563-568.	1.0	30
260	<i><scp>HER</scp>2</i> amplification in squamous cell carcinomas of the vulva. Histopathology, 2013, 62, 965-967.	1.6	2
261	MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using largeâ€scale tissue microarrays. International Journal of Cancer, 2013, 133, 920-928.	2.3	55
262	Immunohistochemical analysis of p16 expression, <scp>HPV</scp> infection and its prognostic utility in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2013, 42, 676-681.	1.4	27
263	High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. Prostate Cancer and Prostatic Diseases, 2013, 16, 159-164.	2.0	7
264	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Experimental and Therapeutic Medicine, 2013, 5, 102-106.	0.8	13
265	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. PLoS ONE, 2013, 8, e54873.	1.1	70
266	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. PLoS ONE, 2013, 8, e84189.	1.1	14
267	Sef Downregulation by Ras Causes MEK1/2 to Become Aberrantly Nuclear Localized Leading to Polyploidy and Neoplastic Transformation. Cancer Research, 2012, 72, 626-635.	0.4	37
268	<i>EGFR</i> gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. Journal of Clinical Pathology, 2012, 65, 133-139.	1.0	30
269	Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Modern Pathology, 2012, 25, 1566-1573.	2.9	46
270	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Pathology, 2012, 44, 448-452.	0.3	11

#	Article	IF	Citations
271	BIRC2 amplification in squamous cell carcinomas of the uterine cervix. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 123-128.	1.4	12
272	PTEN deletion is rare but often homogeneous in gastric cancer. Journal of Clinical Pathology, 2012, 65, 693-698.	1.0	16
273	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer, 2012, 107, 1997-2004.	2.9	68
274	Genome-wide DNA Methylation Events in <i>TMPRSS2â€"ERG</i> Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with <i>miR-26a</i> Hypermethylation. Cancer Discovery, 2012, 2, 1024-1035.	7.7	127
275	Role of cyclin D1 amplification and expression in vulvar carcinomas. Human Pathology, 2012, 43, 1386-1393.	1.1	16
276	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. American Journal of Pathology, 2012, 181, 401-412.	1.9	278
277	Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. Prostate, 2012, 72, 898-903.	1.2	9
278	Prognostic relevance of Bclâ€2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate, 2012, 72, 991-997.	1.2	27
279	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. Journal of Applied Genetics, 2012, 53, 167-174.	1.0	35
280	On the evidence for ESR1 amplification in breast cancer. Nature Reviews Cancer, 2012, 12, 149-149.	12.8	17
281	Intratumoral <scp>T</scp> but not <scp>B</scp> lymphocytes are related to clinical outcome in prostate cancer. Apmis, 2012, 120, 901-908.	0.9	77
282	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer, 2012, 118, 1268-1275.	2.0	48
283	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	0.8	3
284	Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer. PLoS ONE, 2012, 7, e45967.	1.1	8
285	Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 124-124.	0.8	0
286	HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis - reply. Human Pathology, 2011, 42, 910-911.	1.1	1
287	MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. Cancer Biomarkers, 2011, 8, 53-60.	0.8	23
288	No Detection of XMRV in Blood Samples and Tissue Sections from Prostate Cancer Patients in Northern Europe. PLoS ONE, 2011, 6, e25592.	1.1	17

#	Article	IF	Citations
289	Role of TP53 Mutations in Vulvar Carcinomas. International Journal of Gynecological Pathology, 2011, 30, 497-504.	0.9	49
290	The Relationship Between Annual Hospital Volume of Trauma Patients and In-Hospital Mortality in New York State. Journal of Trauma, 2011, 71, 339-346.	2.3	31
291	Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion. Journal of Thoracic Oncology, 2011, 6, 199-202.	0.5	54
292	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. International Journal of Oncology, 2011, 40, 261-8.	1.4	22
293	FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. Journal of Clinical Bioinformatics, 2011, 1, 20.	1.2	12
294	Serum Midkine Correlates with Tumor Progression and Imatinib Response in Gastrointestinal Stromal Tumors. Annals of Surgical Oncology, 2011, 18, 559-565.	0.7	18
295	Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 193-200.	1.4	67
296	TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer, 2011, 11, 507.	1.1	128
297	High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. Prostate, 2011, 71, 281-288.	1.2	224
298	MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma. Cancer Research, 2011, 71, 4226-4235.	0.4	62
299	The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors. Clinical Cancer Research, 2011, 17, 2919-2933.	3.2	118
300	ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy. Clinical Cancer Research, 2011, 17, 5878-5888.	3.2	232
301	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. Cancer Research, 2011, 71, 1362-1373.	0.4	117
302	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation, 2011, 121, 4257-4267.	3.9	153
303	Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 483-490.	1.4	17
304	Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2010, 123, 757-765.	1.1	62
305	Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer, 2010, 10, 295.	1.1	44
306	<i>PPFIA1</i> and <i>CCND1</i> are frequently coamplified in breast cancer. Genes Chromosomes and Cancer, 2010, 49, 1-8.	1.5	20

#	ARTICLE	IF	CITATIONS
307	19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes and Cancer, 2010, 49, 569-575.	1.5	25
308	Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Medical Genetics, 2010, 11, 106.	2.1	31
309	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology, 2010, 57, 418-426.	1.6	30
310	Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncology Letters, 2010, 1, 729-732.	0.8	15
311	Chromosome *8p* Deletions and *8q* Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer. Clinical Cancer Research, 2010, 16, 56-64.	3.2	119
312	Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer. Clinical Cancer Research, 2010, 16, 1553-1560.	3.2	125
313	Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology, 2010, 42, 356-359.	0.3	38
314	Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer. Molecular and Cellular Proteomics, 2010, 9, 161-177.	2.5	45
315	Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. Modern Pathology, 2010, 23, 603-610.	2.9	30
316	Proteomic Profiling of Mammary Carcinomas Identifies C7orf24, a γ-Glutamyl Cyclotransferase, as a Potential Cancer Biomarker. Journal of Proteome Research, 2010, 9, 3941-3953.	1.8	55
317	Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Human Pathology, 2010, 41, 358-365.	1.1	38
318	HER-2 amplification is highly homogenous in gastric cancer—reply. Human Pathology, 2010, 41, 305-306.	1.1	10
319	Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology, 2010, 41, 1577-1585.	1.1	79
320	Loss of Reelin Expression in Breast Cancer Is Epigenetically Controlled and Associated with Poor Prognosis. American Journal of Pathology, 2010, 177, 2323-2333.	1.9	60
321	Applications of Tissue Microarray Technology. Methods in Molecular Biology, 2010, 664, 1-16.	0.4	21
322	Immunohistochemical Analysis of Tissue Microarrays. Methods in Molecular Biology, 2010, 664, 113-126.	0.4	68
323	Recipient Block TMA Technique. Methods in Molecular Biology, 2010, 664, 37-44.	0.4	73
324	HER-2/neu analysis in breast cancer bone metastases. Journal of Clinical Pathology, 2009, 62, 542-546.	1.0	16

#	ARTICLE	IF	CITATIONS
325	Molecular Cancer Phenotype in Normal Prostate Tissue. European Urology, 2009, 55, 885-891.	0.9	23
326	Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate, 2009, 69, 976-981.	1.2	129
327	Estrogen receptor gene amplification occurs rarely in ovarian cancer. Modern Pathology, 2009, 22, 191-196.	2.9	20
328	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nature Medicine, 2009, 15, 674-681.	15.2	172
329	Combined α-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Human Pathology, 2009, 40, 166-173.	1.1	32
330	HER-2 amplification is highly homogenous in gastric cancer. Human Pathology, 2009, 40, 769-777.	1.1	194
331	Tissue Microarrays. Methods in Molecular Biology, 2009, 576, 49-60.	0.4	29
332	AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 243-248.	1.4	32
333	Oestrogen receptor gene (*ESR1*) amplification is frequent in endometrial carcinoma and its precursor lesions. Journal of Pathology, 2008, 216, 151-157.	2.1	35
334	Clinical significance of p53 alterations in surgically treated prostate cancers. Modern Pathology, 2008, 21, 1371-1378.	2.9	180
335	Reply to "ESR1 gene amplification in breast cancer: a common phenomenon?" Nature Genetics, 2008, 40, 810-812.	9.4	47
336	Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. European Urology, 2008, 53, 333-346.	0.9	40
337	Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer. European Urology, 2008, 54, 1314-1323.	0.9	91
338	The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Molecular Oncology, 2008, 1, 431-439.	2.1	43
339	Distinct Gene Expression Profiles: Nodal versus Extranodal Diffuse Large B-Cell Lymphoma. Oncology, 2008, 75, 71-80.	0.9	19
340	Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients. Clinical Cancer Research, 2008, 14, 7838-7842.	3.2	62
341	Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer. Clinical Cancer Research, 2007, 13, 6579-6584.	3.2	144
342	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics, 2007, 39, 655-660.	9.4	351

#	ARTICLE	IF	CITATIONS
343	Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene, 2007, 26, 5680-5691.	2.6	127
344	Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathology, 2007, 20, 120-129.	2.9	171
345	Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Modern Pathology, 2007, 20, 192-198.	2.9	60
346	Epstein â€" Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leukemia and Lymphoma, 2006, 47, 707-713.	0.6	17
347	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. British Journal of Cancer, 2006, 94, 128-135.	2.9	327
348	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Human Pathology, 2006, 37, 453-457.	1.1	21
349	High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. Human Pathology, 2006, 37, 742-748.	1.1	16
350	The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy. Analytical Cellular Pathology, 2006, 28, 223-232.	0.7	21
351	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Modern Pathology, 2006, 19, 1124-1129.	2.9	5
352	E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene, 2006, 25, 6538-6543.	2.6	41
353	The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Research and Treatment, 2006, 97, 275-283.	1.1	193
354	Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 42-52.	3.3	30
355	Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. International Journal of Cancer, 2006, 118, 2190-2194.	2.3	100
356	Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates. Cancer Research, 2006, 66, 2328-2337.	0.4	143
357	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. Journal of Clinical Pathology, 2006, 60, 768-772.	1.0	103
358	Microsatellite DNA Alterations of Gastrointestinal Stromal Tumors Are Predictive for Outcome. Clinical Cancer Research, 2006, 12, 5151-5157.	3.2	22
359	Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Journal of King Abdulaziz University, Islamic Economics, 2006, 27, 323-8.	0.5	10
360	Predominance of high-grade pathway in breast cancer development of Middle East women. Modern Pathology, 2005, 18, 891-897.	2.9	59

#	ARTICLE	IF	CITATIONS
361	High-throughput tissue microarray analysis ofCMYC amplificationin urinary bladder cancer. International Journal of Cancer, 2005, 117, 952-956.	2.3	32
362	Expression and amplification of therapeutic target genes in retinoblastoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 156-162.	1.0	12
363	Tissue Microarrays for Miniaturized High-Throughput Molecular Profiling of Tumors. Biological and Medical Physics Series, 2005, , 345-360.	0.3	0
364	Tissue microarrays. , 2005, , .		0
365	Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder. Clinical Cancer Research, 2005, 11, 4415-4429.	3.2	97
366	Tissue Microarrays. , 2005, 114, 257-268.		45
367	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. International Journal of Oncology, 2005, 27, 385.	1.4	10
368	Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. Biochemical and Biophysical Research Communications, 2005, 329, 318-323.	1.0	8
369	Tissue microarrays. BioTechniques, 2004, 36, 98-105.	0.8	99
370	Tissue Microarrays. , 2004, 97, 377-390.		17
371	Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer. Cancer Research, 2004, 64, 8534-8540.	0.4	306
372	KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations. Clinical Cancer Research, 2004, 10, 178-183.	3.2	97
373	Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International Journal of Oncology, 2004, 25, 641.	1.4	62
374	Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma. Cancer Research, 2004, 64, 1632-1638.	0.4	87
375	Prevalence of KIT Expression in Human Tumors. Journal of Clinical Oncology, 2004, 22, 4514-4522.	0.8	212
376	E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene, 2004, 23, 5616-5623.	2.6	141
377	Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Laboratory Investigation, 2004, 84, 465-478.	1.7	134
378	Influence of slide aging on results of translational research studies using immunohistochemistry. Modern Pathology, 2004, 17, 1414-1420.	2.9	102

#	Article	IF	Citations
379	High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer. Breast Cancer Research and Treatment, 2004, 86, 207-213.	1.1	211
380	Tissue microarrays for early target evaluation. Drug Discovery Today: Technologies, 2004, 1, 41-48.	4.0	10
381	Tissue microarrays for high-throughput molecular pathology. Annals of Saudi Medicine, 2004, 24, 169-174.	0.5	21
382	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. Blood, 2004, 104, 4609-4609.	0.6	0
383	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkin's Lymphoma in Saudi Arabia.. Blood, 2004, 104, 3120-3120.	0.6	0
384	HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. International Journal of Oncology, 2004, 25, 1551-7.	1.4	19
385	Sequence analysis and high-throughput immunhistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 741-744.	1.4	57
386	HER-2 andTOP2A coamplification in urinary bladder cancer. International Journal of Cancer, 2003, 107, 764-772.	2.3	93
387	High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. Journal of Pathology, 2003, 201, 603-608.	2.1	84
388	Tissue microarrays in drug discovery. Nature Reviews Drug Discovery, 2003, 2, 962-972.	21.5	178
389	Tissue microarrays in cancer diagnosis. Expert Review of Molecular Diagnostics, 2003, 3, 421-430.	1.5	62
390	Tissue microarray (TMA) applications: implications for molecular medicine. Expert Reviews in Molecular Medicine, 2003, 5, 1-12.	1.6	33
391	Predictive Molecular Pathology. New England Journal of Medicine, 2002, 347, 1995-1996.	13.9	32
392	Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Experimental Hematology, 2002, 30, 1365-1372.	0.2	96
393	Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study. International Journal of Cancer, 2002, 100, 702-705.	2.3	65
394	Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. Journal of Pathology, 2002, 197, 575-581.	2.1	86
395	Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. Journal of Pathology, 2002, 198, 115-120.	2.1	34
396	Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene, 2002, 21, 2476-2483.	2.6	142

#	ARTICLE	IF	CITATIONS
397	Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. Journal of Pathology, 2001, 194, 165-170.	2.1	148
398	Comparative genomic hybridization in pineal parenchymal tumors. Genes Chromosomes and Cancer, 2001, 30, 99-104.	1.5	62
399	Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2001, 93, 1141-1146.	3.0	284
400	Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Research, 2001, 61, 355-62.	0.4	90
401	High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Research, 2001, 61, 4514-9.	0.4	120
402	Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology, 2000, 37, 411-419.	1.6	63
403	Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 2000, 406, 536-540.	13.7	1,877
404	Patterns of chromosomal imbalances in muscle invasive bladder cancer.. International Journal of Oncology, 2000, 17, 1025-9.	1.4	21
405	Comparative genomic hybridization of ductal carcinomain situ of the breast?evidence of multiple genetic pathways. , 1999, 187, 396-402.		291
406	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. , 1999, 189, 521-526.		211
407	Chromosomal Aberrations Associated With Invasion in Papillary Superficial Bladder Cancer. Journal of Urology, 1999, 162, 621-621.	0.2	0
408	Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways. , 1999, 187, 396.		1
409	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. , 1999, 189, 521.		2
410	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1998, 185, 345-351.		129
411	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1998, 185, 345.		1
412	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. , 1998, 185, 345.		3
413	COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY. , 1997, 181, 394-400.		91